410 related articles for article (PubMed ID: 33037044)
1. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
3. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
Costales C; Lin J; Kimoto E; Yamazaki S; Gosset JR; Rodrigues AD; Lazzaro S; West MA; West M; Varma MVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1018-1031. PubMed ID: 34164937
[TBL] [Abstract][Full Text] [Related]
4. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
5. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
Wang Q; Zheng M; Leil T
CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
[TBL] [Abstract][Full Text] [Related]
6. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
[TBL] [Abstract][Full Text] [Related]
7. Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
Chen Y; Zhu R; Ma F; Mao J; Chen EC; Choo EF; Sahasranaman S; Liu L
Biopharm Drug Dispos; 2018 Nov; 39(9):420-430. PubMed ID: 30335192
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
9. Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics.
Taguchi T; Masuo Y; Futatsugi A; Kato Y
Drug Metab Dispos; 2020 Sep; 48(9):750-758. PubMed ID: 32616544
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Elsby R; Coghlan H; Edgerton J; Hodgson D; Outteridge S; Atkinson H
Pharmacol Res Perspect; 2023 Apr; 11(2):e01060. PubMed ID: 36811234
[TBL] [Abstract][Full Text] [Related]
11. Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.
Farasyn T; Crowe A; Hatley O; Neuhoff S; Alam K; Kanyo J; Lam TT; Ding K; Yue W
J Pharm Sci; 2019 Oct; 108(10):3443-3456. PubMed ID: 31047942
[TBL] [Abstract][Full Text] [Related]
12. Pre-incubation with OATP1B1 and OATP1B3 inhibitors potentiates inhibitory effects in physiologically relevant sandwich-cultured primary human hepatocytes.
Farasyn T; Pahwa S; Xu C; Yue W
Eur J Pharm Sci; 2021 Oct; 165():105951. PubMed ID: 34311070
[TBL] [Abstract][Full Text] [Related]
13. Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
Chang M; Bathena S; Christopher LJ; Shen H; Roy A
Cancer Chemother Pharmacol; 2022 Mar; 89(3):383-392. PubMed ID: 35147740
[TBL] [Abstract][Full Text] [Related]
14. Improving the Translation of Organic Anion Transporting Polypeptide Substrates using HEK293 Cell Data in the Presence and Absence of Human Plasma via Physiologically Based Pharmacokinetic Modeling.
Bowman CM; Chen B; Cheong J; Liu L; Chen Y; Mao J
Drug Metab Dispos; 2021 Jul; 49(7):530-539. PubMed ID: 33958385
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
16. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
Shoaf SE; Bricmont P; Repella Gordon J
Clin Transl Sci; 2021 Jul; 14(4):1535-1542. PubMed ID: 33742787
[TBL] [Abstract][Full Text] [Related]
17. Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions.
Mochizuki T; Zamek-Gliszczynski MJ; Yoshida K; Mao J; Taskar K; Hirabayashi H; Chu X; Lai Y; Takashima T; Rockich K; Yamaura Y; Fujiwara K; Mizuno T; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
Clin Pharmacol Ther; 2022 Jun; 111(6):1315-1323. PubMed ID: 35292967
[TBL] [Abstract][Full Text] [Related]
18. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
19. P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV.
Moreira FL; Melli PPDS; Marques MP; Rocha A; Nardotto GHB; Duarte G; Lanchote VL
J Clin Pharmacol; 2023 Feb; 63(2):219-227. PubMed ID: 36087110
[TBL] [Abstract][Full Text] [Related]
20. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
